Adoptive T Cell Therapy Using Educated T Cells Generated by the Sequential Stimulation with DC/Tumor Fusion Cells and Anti-CD3CD28
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Natalya Rozenveyn, Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Corrine Zarwan(Beth Israel Deaconess Medical Center), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), James D. Levine(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), Thea M. Friedman(Hackensack University Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k